| 0.496 -0.008 (-1.65%) | 10-22 15:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.69 | 1-year : | 0.78 |
| Resists | First : | 0.59 | Second : | 0.67 |
| Pivot price | 0.53 |
|||
| Supports | First : | 0.46 | Second : | 0.38 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.54 |
| MA(100) : | 0.6 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 17.2 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 2.51 | Low : | 0.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JSPR ] has closed above bottom band by 26.3%. Bollinger Bands are 48.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.54 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.5 - 0.5 | 0.5 - 0.51 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Thu, 15 Oct 2026
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. - Stock Titan
Wed, 07 Oct 2026
All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. - Stock Titan
Mon, 05 Oct 2026
After closing roughly $132M in financing, Jasper Therapeutics (JSPR) reports illustrative combined losses. - Stock Titan
Mon, 17 Aug 2026
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Thu, 16 Jul 2026
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals - GlobeNewswire
Wed, 03 Jun 2026
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 39.2 (%) |
| Shares Short | 6,220 (K) |
| Shares Short P.Month | 5,490 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 9.9 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|